Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CJCV2 Vaccine With and Without ALFQ Adjuvant in Healthy Adults
NCT05500417Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2022
- Primary completion
- Jan 2025
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Campylobacter jejuni Conjugate Vaccine in campylobacteriosis (6 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number and Percentage of Participants With Solicited Local Adverse Events (AEs), Number and Percentage of Participants With Solicited Systemic Adverse Events (AEs) and 5 more. Started Sep 2022; status: completed.
02
Drugs
Campylobacter jejuni Conjugate Vaccine
03
Conditions
campylobacteriosis
Beyond the preview
Go deeper on NCT05500417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05500417.